4.8 Article

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 132, 期 11, 页码 -

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI146471

关键词

-

资金

  1. Cancer Prevention and Research Institute of Texas [RP110595-P1]
  2. National Cancer Institute [R01 CA 135354]
  3. NIH/National Cancer Institute [R01CA135354]
  4. Specialized Program of Research Excellence in Ovar-ian Cancer from the National Cancer Institute [CA 217685]
  5. MD Anderson Cancer Center Support grant from the National Cancer Institute [P30 CA16672]
  6. National Foundation for Cancer Research
  7. NIH/National Center for Advancing Translational Sciences [UH3TR00943-01]
  8. NCI [1R01 CA182905-01, 1R01CA222007-01A1]
  9. Team DOD grant [CA160445P1]
  10. Computational Cancer Biology Training Program fellowship, Cancer Prevention Research Institute of Texas [RP170593]

向作者/读者索取更多资源

PARP inhibitors selectively target cancer cells with homologous recombination DNA repair deficiency, but resistance eventually develops. SIK2 inhibitors have been found to enhance the sensitivity of ovarian and triple-negative breast cancer cells to PARP inhibitors through suppressing DNA repair functions and gene transcription.
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations in BRCA1/2 and other DNA repair pathway genes. Cancers with homologous recombination DNA repair proficiency respond poorly to PARP inhibitors. Cancers that initially respond to PARP inhibitors eventually develop drug resistance. We have identified salt-inducible kinase 2 (SIK2) inhibitors, ARN3236 and ARN3261, which decreased DNA double-strand break (DSB) repair functions and produced synthetic lethality with multiple PARP inhibitors in both homologous recombination DNA repair deficiency and proficiency cancer cells. SIK2 is required for centrosome splitting and PI3K activation and regulates cancer cell proliferation, metastasis, and sensitivity to chemotherapy. Here, we showed that SIK2 inhibitors sensitized ovarian and triple-negative breast cancer (TNBC) cells and xenografts to PARP inhibitors. SIK2 inhibitors decreased PARP enzyme activity and phosphorylation of class-IIa histone deacetylases (HDAC4/5/7). Furthermore, SIK2 inhibitors abolished class-IIa HDAC4/5/7-associated transcriptional activity of myocyte enhancer factor-2D (MEF2D), decreasing MEF2D binding to regulatory regions with high chromatin accessibility in FANCD2, EXO1, and XRCC4 genes, resulting in repression of their functions in the DNA DSB repair pathway. The combination of PARP inhibitors and SIK2 inhibitors provides a therapeutic strategy to enhance PARP inhibitor sensitivity for ovarian cancer and TNBC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据